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Methods to reimburse living organ donors for the non-
medical expenses they incur have been implemented
in some jurisdictions and are being considered in oth-
ers. A global understanding of existing legislation and
programs would help decision makers implement and
optimize policies and programs.
We searched for and collected data from countries that
practice living organ donation. We examined legisla-
tion and programs that facilitate reimbursement, fo-
cusing on policy mechanisms, eligibility criteria, pro-
gram duration and types of expenses reimbursed.
Of 40 countries, reimbursement is expressly legal in
16, unclear in 18, unspecified in 6 and expressly pro-
hibited in 1. Donor reimbursement programs exist in
21 countries; 6 have been enacted in the last 5 years.
Lost income is reimbursed in 17 countries, while travel,
accommodation, meal and childcare costs are reim-
bursed in 12 to 19 countries. Ten countries have com-
prehensive programs, where all major cost categories
are reimbursed to some extent. Out-of-country donors
are reimbursed in 10 jurisdictions. Reimbursement is
conditional on donor income in 7 countries, and recip-
ient income in 2 countries.
Many nations have programs that help living donors
with their financial costs. These programs differ in op-
eration and scope. Donors in other regions of the world
are without support.
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Introduction
About 27 000 living kidney transplants occur around the
world each year, and the number is increasing (1). In ad-
dition, about 2000 living donor liver transplants are per-
formed annually (2) and 250 living donor lung transplants
have been performed worldwide (3). Living donor kidney
transplantation is preferred to deceased donor transplan-
tation or dialysis, as it improves recipient outcomes at a
reduced cost to the healthcare system (4). It is estimated
that one living kidney donation results in a net increase of
2 to 3.5 quality-adjusted life-years, and a net health care
savings of $100 000 Canadian (5).
Non-medical expenses are frequently incurred by the liv-
ing organ donor as part of the transplant process (6).
These expenses include travel, parking, accommodation,
meal and dependent care costs, as well as lost income.
One Canadian study estimated that 53% of organ donors
incur transportation and parking costs (7). In another
American multi-center study, transportation and accommo-
dation costs were reported by 99% and 88% of donors,
respectively (8). Lost income has been reported in 14–30%
of organ donors, averaging as much as $4410 Canadian in
2004 (7,9,10). In a single center study involving 133 poten-
tial donors to a family member, 24% chose not to donate
because of anticipated financial hardship (11).
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To ease the financial burden of organ donation, experts ad-
vocate reimbursement of legitimate expenses, stating that
it is just and ethically responsible, and should be consid-
ered a cost associated with treating living organ recipients
(12–18). In 2008, the Declaration of Istanbul on Organ Traf-
ficking and Transplant Tourism, the European Parliament,
and the Asian Taskforce on Organ Trafficking each issued
formal statements urging member states to define condi-
tions in which reimbursement can be granted (12,13,16).
All groups make a clear distinction between the acceptable
practice of reimbursement of legitimate expenses incurred
as a result of the transplant process, and payment resulting
in financial gain which is illegal in most jurisdictions.
A comprehensive understanding of existing reimburse-
ment programs would provide a global context for decision
makers as they look to implement or refine reimbursement
programs within their jurisdictions. The lack of a published




We considered countries where 10 or more living donations are performed
each year, based on an average between 2004 and 2007 as described in the
Global Observatory on Organ Transplantation and Horvat et al. (1,2). While
reimbursement is implicit in payment programs, we excluded programs
where payment is intended for financial gain, as this practice contravenes
international recommendations and standards (12,16,19,20).
The data collection plan is presented in Figure 1. We first determined if
reimbursement of legitimate expenses was legal in member countries.
Based on legislation, the legality of reimbursement was classified into one
of four categories: legal, illegal, unclear and unspecified. An example of
a reimbursement clause that was interpreted as legal was ‘[1] A person
commits an offence if he [a] gives or receives a reward for the supply
of, or for an offer to supply, any controlled material;. . .[6]. . . payment in
money or money’s worth to the holder of a license shall be treated as not
being a reward where [a] it is in consideration for transporting, removing,
preparing, preserving or storing controlled material (21)’. We were not able
to find a clause that was interpreted as illegal; reimbursement would have
been categorized illegal if the legislation clearly stated that reimbursement
of expenses incurred during the organ donation process, as opposed to
reimbursement for an organ, was prohibited. Unclear legislation did not
explicitly address the issue of reimbursement for non-medical expenses,
but addressed the issue of organ and/or tissue donation. An example of an
unclear clause was ‘no person shall buy, sell or otherwise deal in, directly
or indirectly, for a valuable consideration, any tissue for a transplant (22)’.
Unspecified refers to legislation that did not address the broader subject of
organ and/or tissue donation or when the country representative indicated
otherwise. Countries with provincial legislation, where provinces differed
in their legislation, were counted in all applicable categories. Therefore,
the sum of the number of countries across all types of legislation may be
greater than the total number of countries.
We then ascertained characteristics of programs that facilitate donor reim-
bursement, including program history, mechanisms, types of non-medical
expenses reimbursed (travel, accommodation, meals, lost income and child-
care) and eligibility criteria (Figure 1). We also gathered information on
“umbrella” programs, which compensate donors as part of other broader
initiatives. Information on national programs was collected for countries
with both national and provincial/territorial/state reimbursement initiatives.
Countries with provincial programs, where provinces differed in program
details, were counted in all applicable categories. Therefore, the sum of
the number of countries in each program category may be greater than the
total number of countries.
Data sources and collection
Data collection was updated until July 2009. [Correction made after online
publication 4 Nov 2009: 2008 changed to 2009] Data were extracted by a
single author (MS) from government and ministry websites, legal databases
(International Digest of Health Legislation and World Legal Information In-
stitute), and kidney, nephrology and transplantation foundations’ websites.
Data were independently reviewed for accuracy by a second author (MC).
In most cases, information was also collected directly from country rep-
resentatives by the same single author (MS) in order to obtain English
language legislation or to obtain information that was not available from
other sources (Appendix A). Country representatives included members of
Is reimbursement legal?
Yes NoUnclear
Is there a program which facilitates reimbursement?
Yes No





























Figure 1. Flow chart of data col-
lected for each eligible coun-
try. ∗Non-medical expenses included
travel, accommodation, meals, lost in-
come and childcare.
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national kidney, nephrology and transplant foundations, Ministries of Health,
and health care providers involved in living organ transplantation. All data
that were not collected directly from country representatives were sent to
representatives for verification. Legislation that was not available in English
was obtained in the native language and translated with the help of a coun-
try representative, a translator, Google Translator (translate.google.com) or
Yahoo Babel (babelfish.yahoo.com).
Results
One hundred ninety-three countries were considered for
this review. One hundred twenty-one countries were ex-
cluded: the Global Observatory on Organ Transplantation
(2) did not recognize 88 nations as performing living organ
donation (LOD); data on the number of LODs per year were
missing for 14 countries; all LODs were performed outside
of 1 country; a country representative confirmed that LOD
was illegal in 1 country; less than 10 LODs were performed
per year on average between 2004 and 2007 in 16 coun-
tries and a legal payment program had been established in
1 country. In total, 72 countries were eligible. We were able
to collect data from 40 (56%) countries. For the remaining
32 nations, data collection was either incomplete due to
unavailability of information and/or because the country
representative was non-responsive. Data sources for each
country are provided in Appendix B.
Of the 40 countries examined, 16 expressly legalize re-
imbursement, 1 explicitly prohibits any form of compen-
sation, 18 have unclear legislation and 6 are unspecified.
Legislation or information on legislation was not available
for 2 countries.
Reimbursement programs exist in 21 of the 40 countries;
14 programs in the 16 countries where reimbursement
is expressly permitted by law, another 8 programs in the
18 countries where legislation is unclear and 1 in the 6
countries where reimbursement is unspecified (Table 1).
Six of the 21 countries implemented reimbursement pro-
grams in the past 5 years (Australia, Canada, New Zealand,
Saudi Arabia, the United Kingdom and the United States).
Two countries (Israel and Singapore) are in the process
of implementing a program that will take effect within the
year 2009. Permanent reimbursement programs exist in 20
countries; 2 countries have programs in a pilot phase (USA
and Canada). Representatives from 7 countries indicated
their reimbursement programs were currently being re-
evaluated or improved (Belgium, France, the Netherlands,
New Zealand, Saudi Arabia, Switzerland and the United
States). Of the 18 countries in which reimbursement is
not illegal and no program exists, representatives from 2
countries indicated active pursuit of a donor reimburse-
ment program (Austria and India).
As shown in Table 2, 10 countries have comprehensive
programs where 5 major types of costs (travel, accommo-
dation, meals, lost income and childcare) are reimbursed
in some capacity. Most of the 21 countries with pro-
grams reimburse some lost income (17 countries), travel
expenses (19 countries) and accommodation (17 coun-
tries). A smaller number of countries reimburse meals
(14 countries) and childcare costs (12 countries). Out-of-
province/state/country donors are eligible for reimburse-
ment in 10 jurisdictions. Reimbursement is conditional on
donor income in 7 countries, and on recipient income in 2
of these countries (Bolivia and the United States). In one
country (Bolivia) the recipient and donor have the option to
meet with a lawyer to negotiate the type and amount of
reimbursement to be granted the donor by the recipient;
this can include travel, accommodation, meal and other
postsurgical expenses (Table 2).
Health care travel assistance programs exist in some coun-
tries, providing financial assistance to all types of patients
including living organ donors. For example, a program in
Australia reimburses donors for travel, accommodation and
meals (Travel Reimbursement Policy offered by Western
Australia Country for Health Services). Programs in Canada
reimburse similar costs (Canadian Medical Transportation
Assistance Program in Newfoundland and Labrador; North-
ern Health Travel Grant in Ontario) (Tables 2 and 3).
Countries have differing sources of funding for reimburse-
ment; some countries have multiple sources. In 15 of the
20 countries with programs, reimbursement is at least
partially government funded. In 5 countries, lost income
can be covered in some capacity by the donor’s employer
through sick leave, paid leave and/or employment insur-
ance (Belgium, Canada, Czech Republic, the United King-
dom and the United States). In 3 countries donors receive
reimbursement from charity organizations (Canada, the
Philippines and Saudi Arabia). Funds are available through
the recipient’s health/sickness insurance in 4 countries
(Germany, Netherlands, Switzerland and Turkey). In Bolivia,
where the recipient and donor can meet with a lawyer to
agree upon donor reimbursement, the recipient may be
responsible for reimbursing the donor (Table 3). Similarly,
in Singapore, the recipient may choose to reimburse the
donor and those who are unable to afford reimbursement
may be referred to volunteer welfare organizations for as-
sistance (Table 3).
Programs and policies in specific jurisdictions
The United States’ National Living Organ Donor Assistance
Program (NLODAP) is a 4-year pilot program (commenced
in October 2007), that is unique in the way it determines
which donors are eligible for compensation. This program
considers both donor and recipient income and classifies
each donor into one of four categories based on financial
need. Preference is given to low-income donors with low-
income recipients; donors are ineligible for reimbursement
when donor and recipient have incomes greater than 300%
above the poverty line. An additional distinguishing feature
of the NLODAP is that it provides donors with a prepaid
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Country Province/territory/state/region unspecified, illegal) exist?
Australia Australian Capital Territory Legal No
New South Wales Legal No
Northern Territory Legal No
Queensland Unclear No
South Australia Legal No
Tasmania Legal No
Victoria Legal No





Bosnia and Herzegovina Unspecified No
Brazil Unclear No
Canada Alberta Unclear Yes
British Columbia Unclear Yes
Manitoba Legal Yes
New Brunswick Unclear Yes
Newfoundland and Labrador Unclear Yes
Northwest Territories Unspecified Yes
Nova Scotia Unclear Yes
Ontario Unclear Yes























Saudi Arabia Legal Yes
Singapore Legal Yes







United Kingdom Legal Yes
United States Legal Yes
Venezuela Unclear No
N/A = data not available.
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Table 3: Summary of non-medical expense reimbursement opportunities
Province/territory/ Name and type Program mechanisms
Country state/region of program Source of funds and additional details
Australia Western Australia Western Australia
Country Health Service
(WACHS)
Government Donors must provide travel and
accommodation receipts, along with
supporting taxation receipts and
documentation. Escort expenses are not
reimbursable. Only Western Australia
residents traveling to Perth are covered.
Belgium Umbrella program Government and
employer
Only lost income is covered. During the first
month of incapacity, 100% of the donor’s
salary is paid by the employer. After the first
month, 60% of the lost income is covered
by insurance/mutuelle. All citizens have a
‘mutuelle’ which provides reimbursement
for medications, hospitalizations and
operations.
Bolivia No formal program Recipient The recipient and donor have the option to
meet with a lawyer to negotiate the type
and amount of reimbursement to be
granted the donor by the recipient; this can
include travel, accommodation, meals and
other postsurgical expenses This is possible
only when transplant is done at private
center. There is no government involvement
during this process.
Canada Alberta No formal program Charity (Hope Air) Social workers work with Hope Air to assist
with air transportation expenses; they also
attempt to facilitate financial support
through various charitable organizations.









Two-step process: (1) predicted expenses
are submitted for preapproval, (2) expense
claim forms and receipts are submitted
following surgery and assessment stages.




New Brunswick No formal program Government and
charities
All transportation, meal and
accommodation expenses are reimbursed,
provided receipts. Donor out-of-pocket
expenses are submitted to the Provincial
Donor Coordinator who recommends
reimbursement to the Department of
Health and Wellness Hospital Services
Branch. Social workers assess the donor’s
need for other types of expenses.
Newfoundland and
Labrador
Umbrella program Government The Medical Transportation Assistance
Program states that donors are required to
pay medical and travel expenses
out-of-pocket and subsequently apply for
reimbursement of allowable expenses.
Expenses are assessed based on travel
dates in relation to medical
appointment/service date(s). Applicants
must provide receipts and boarding passes
for air travel for eligible expenses.
Canada Northwest Territories Umbrella program Government The Medical Travel Assistance Policy states
that travel must originate in the NWT and
health care must not be available within the
resident’s home community. A co-payment
fee is required for every round-trip.
Continued.
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Table 3: Continued
Province/territory/ Name and type Program mechanisms
Country state/region of program Source of funds and additional details
Nova Scotia No formal program Charity (Hope Air) Charitable help is available.
Ontario Program for
reimbursing expenses
of living organ donors
Government and
employer
The program is a last resort for donors.
Donors apply for reimbursement through
the Trillium Gift of Life Network,
administering the program on behalf of
Ministry of Health and long-term care. For
lost income, the donor is expected to apply
for reimbursement from his/her employer




The Northern Health Travel Grant defrays
transportation costs for residents of
Northern Ontario who must travel long
distances within Ontario or Manitoba to
receive health care services not available
locally; applicants must apply for
reimbursement, and must live at least
100 km from the nearest facility.
Prince Edward Island No formal program Government and
charity
Any reimbursement, above travel expenses,
is generally provided for donors with
financial issues and is provided by
non-governmental sources, through the
help of social workers.
Saskatchewan Umbrella program Employer An agreement is made between the donor
and his/her employer for paid leave during
transplant process.
No formal program Charity (Kinsmen
Foundation)
Social workers contact charitable
organizations to check availability of funds,
and the donor’s suitability for assistance.
Chile No formal program Government and
private system
All donors receive reimbursement for time
away from work. Donors must apply before
the transplant surgery or up to
48 h after transplant surgery, and physician
signature is required.
Czech Republic No formal program Government, recipient
health insurance and
employer
Donors receive a social security payment to
substitute lost income during
hospitalization. Travel expenses are covered
by recipient health insurance. Recipients
must apply for reimbursement.
Out-of-country donors may be eligible with
prior approval. Minimal salary loss is
covered by employer.
Denmark Reimbursement
included in health care
system
Government Expenses are estimated and paid by the
hospital; the hospital is then reimbursed by
government. The system for
reimbursement was expanded in 2003 to
cover a reasonable amount of medical
examinations postdonation.
France Reimbursement
included in health care
system
Government The health care establishment reimburses
the donor and is then reimbursed by social
security public insurance. There is no
maximum amount reimbursable; most
reasonable expenses are covered. A new
decree is in preparation and will be
published by 2009; substantial changes will
be implemented, including the shift of the
payer role to national or regional social
security instead of the healthcare
establishment.
Continued.
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Table 3: Continued
Province/territory/ Name and type Program mechanisms
Country state/region of program Source of funds and additional details
Germany No formal program Recipient Health
Insurance
Travel, accommodation and some lost
wages are automatically covered by the
recipient’s health insurance. Travel abroad is
covered along with medical costs through
health insurance and sickness benefits
under the national social security program.
Lost income is partially reimbursed by the
recipient’s employer as sick leave; a new
proposal has been submitted to standardize
reimbursement for loss of income.
Umbrella program
Israel Organ Transplant Bill:
Financial
Compensation Package
and a series of benefits
Government Expenses are reimbursed via a
compensation package that depends on
donor income. This is in addition to a series
of other benefits (recovery of expenses for
psychological treatment, recovery leave,
merit certificate from State and free
entrance to nature reserves and national
parks).
Netherlands No formal program Government and
recipient sickness
insurance
The Dutch Kidney Foundation is awarded a
grant from the Dutch Ministry of Health,
Welfare and Sport. Any donor can apply for
reimbursement through the Kidney
Foundation before or after expenses are
incurred. Lost income is also repaid through
this program for a maximum of 6 weeks, in
case of sever e complications it can cover
up to 12 weeks. Reimbursement of all
non-medical costs not covered by sickness
insurance is provided by the government.




Government Reimbursement is tax free and subject to
limits. Donors must apply to District Health
Board. Payments are made directly to the
donor’s bank account with proof of lost
income and dependents’ birth certificates.
Donors are eligible for reimbursement for






Government A completed claim form is required for
reimbursement, along with itemized
receipts. Some accommodation expenses
may be covered by District Health Board.




Government Recipients apply for reimbursement with
proof of expenses. There is no maximum
amount reimbursable, provided that








The Transplantation Foundation of the
Philippines reports rejecting offers from
potential organ donors seeking to ‘sell’ an
organ. The total reimbursement package is
fixed. The donor must apply to the
Foundation.
Continued.
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Table 3: Continued
Province/territory/ Name and type Program mechanisms
Country state/region of program Source of funds and additional details






Saudi riyals may be reimbursed and
awarded the King Abdul Aziz medal of the
third degree and a discount card with
Saudi airlines. SCOT (a governmental
agency) coordinates the dispensing of
incentives with the ministry of health.
Donors can decline the incentive. The
reimbursement committee meets with the
unrelated living donor and interviews him
at least 3 times to make sure that he is
donating out of his conscience and with
complete willingness, not out of poverty,
need or pressure. The Prince Fahed Ibn
Salman Charitable Society has the right to
supervise reimbursement.
Singapore No formal program Recipient, and
voluntary welfare
organizations
Donor may be reimbursed for donation
related expenses such as travel,
accommodation, medical and surgical,
loss of income and miscellaneous
expenses such as eldercare and childcare.
Recipients who cannot afford to reimburse
their donor can be referred to voluntary
welfare organizations for assistance.




Government Donors must apply for reimbursement,
providing receipts of expenses, and
proving loss of income. Reimbursement is
facilitated by social workers. Expenses are
paid for out-of-pocket by the donor and the
donor is then reimbursed. All costs are
reimbursed if proper documentation is
provided.
Switzerland No formal program Recipient Health
Insurance; Health care
system
Reimbursement is administered by the
association of medical insurance. All
expenses within reason are reimbursable.
Turkey No formal program Recipient’s Social
Insurance
The donor’s physician must provide a
sickness report for the donor in order for
the donor to receive reimbursement for
transportation as well as accompanying
person expenses through the recipient’s
social insurance. Accommodation and
meals outside of hospital are not covered.







Expenses are covered by the donor
out-of-pocket; the donor is then
reimbursed. Donors must claim expenses
before expenses are incurred, within 12
weeks of surgery. Personal expenses are
repaid in full once receipts are provided.
Mileage can be reimbursed at the
standard National Health Service rate.
Payments are not subject to tax liability.
Tax liability for loss of earnings depends
on the employment status of the donor.
Payments for loss of earnings are legal
under the HOT Act but the method of
payment and position with respect to any
tax liability depends on the employment
status of the individual.
Continued.
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Table 3: Continued
Province/territory/ Name and type Program mechanisms
Country state/region of program Source of funds and additional details




Donors must apply online before expenses
are incurred. A review committee then
votes on the eligibility of the donor. Escort
expenses are reimbursable. The maximum
number of donors per recipient for
reimbursement is 3 for kidney, 5 for liver
and 6 for lung donations. Amount of
reimbursement depends on the amount of
reimbursement received from other
sources, such as employment insurance
policies.
TBD = to be determined.
credit card for use during the donation process, instead of
reimbursing costs that have already been incurred.
Reimbursement programs exist in many European coun-
tries. In France and Denmark, reimbursement of expenses
is required for all donors undergoing a live organ trans-
plant; hospitals automatically reimburse donors and are
subsequently reimbursed by the government.
Donor reimbursement programs are less common in South
America (23).
Saudi Arabia and Israel both offer a series of benefits to
ensure that donors do not suffer as a result of their dona-
tions. Saudi Arabia provides long-term medical insurance
to aid donors with future medical care. Israel will supply
donors with insurance against the loss of ability to work
or loss of earning power as well as life insurance so that
these benefits remain affordable after surgery. Rewards of
non-monetary value are offered as well, such as a discount
on Saudi Airlines or free entrance to national parks in Is-
rael. If needed, Israel will also cover psychologist expenses
to ensure that donors make a full recovery after surgery.
Finally, in both Israel and Saudi Arabia, a modest financial
package that depends on donor income will be provided
to reimburse all donors for their non-medical expenses
such as lost income, lost days of sick-leave and travel
expenses.
Reimbursement programs are sparse across Asia. How-
ever, in Singapore, an amendment to the Human Organ
Transplant Act, allowing reimbursement of reasonable ex-
penses in relation to organ donation, was recently passed.
The new law allows recipients to reimburse donors for their
incurred medical and non-medical expenses. In addition,
in India, living donor benefits have been recommended
by the Transplant of Human Organs Act (THOA) review
committee. Existing THOA law permits compensation for
the loss of wages but it is not practiced since the same
could be interpreted as sale or purchase of organs. The
National Organ Transplant Program is in the process of
being implemented; coverage of medical expenses and
medical insurance for the donor, as well as travel conces-
sions on Indian railways, are under consideration for the
program.
Discussion
This is the first comprehensive review of global legisla-
tion and procedures to reimburse living organ donors for
their financial costs. Living organ donor reimbursement
programs have recently been introduced in many coun-
tries, in some cases as a pilot project. In other countries
de novo programs are under development. Many programs
differ in their operation, funding source and expenses reim-
bursed. We described existing programs, funding sources,
eligibility criteria and categories of donor cost that are re-
imbursed.
In most reimbursement programs, non-medical expenses
are paid directly or indirectly (via health care) from gov-
ernment sources. Some programs rely on charities and
employers; very few programs rely on the recipient (ei-
ther through direct payment or through health care insur-
ance). Almost half of the reimbursement programs are
comprehensive in that they cover the 5 major types of
non-medical expenses (travel, accommodation, meals, lost
income and childcare). For the countries with compre-
hensive reimbursement, donors in 8 countries can apply
through one source to receive reimbursement. Of the 6
programs that were initiated in the last 5 years, 2 are com-
prehensive. We were unable to determine if all costs in-
curred by living donors were reimbursed through existing
programs.
Limitations of our review merit discussion. As for all re-
views of this type, the accuracy of the results is highly
dependant on the quality of the data collected. We com-
piled data from 40 of the 72 countries eligible for review.
Despite repeated attempts we were unable to obtain in-
formation for 32 of the 72 countries that practice living
2834 American Journal of Transplantation 2009; 9: 2825–2836
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donation, such as Columbia, Cyprus and Georgia. How-
ever, this may not materially impact the results presented,
as we believe it is reasonable to assume such countries do
not have reimbursement programs.
We did not collect information on monetary values for re-
imbursement. A paper focusing solely on program details
would be the ideal setting in which to collect and present
such data.
The data acquired from the 40 countries were derived from
a variety of sources, as a single source for international leg-
islation and information on reimbursement programs does
not exist. Information obtained for this review was at risk
for being outdated, biased or untranslatable. To address
these deficiencies, we undertook the additional step of
contacting country representatives to confirm the accu-
racy of the data. Information obtained from country repre-
sentatives, however, may be subject to bias and is directly
limited by the individual’s experience in living organ do-
nation. In some countries, multiple complex opportunities
for reimbursement exist, including programs beyond the
sphere of transplantation (18). We provided generalizations
of these opportunities to allow for broader comparisons
across countries. We could not determine whether donors
had difficulties accessing current programs, nor to what
extent programs reimbursed incurred donor costs. The de-
gree to which reimbursement programs improve satisfac-
tion with the transplant process, and transplant rates, re-
mains the subject of further research.
In summary, this review provides a comprehensive
overview of legislation and practices of living organ donor
reimbursement worldwide. Many programs have recently
been enacted, and several nations are considering imple-
menting de novo reimbursement programs. Despite this,
most living organ donors worldwide lack organized pro-
grams to defray the costs of the donation process. This
summary will allow decision makers and transplant profes-
sionals to frame current programs in the global context, and
will aid development and refinement of optimal reimburse-
ment policies. Given the emerging practice of living organ
donor reimbursement, it may be prudent for countries that
expressly prohibit reimbursement to reassess current leg-
islation in light of global practices and current international
recommendations. It is our hope that the information pre-
sented here can be used to assist those countries yet to
develop local programs, and refine existing programs.
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